Adherence to buprenorphine-XR through hybrid telehealth contingency management procedures: a case series

References

• Ariss, T., & Fairbairn, C. E. (2020). The effect of significant other involvement in treatment for substance use disorders: A meta-analysis. Journal of Consulting and Clinical Psychology, 88(6), 526. https://doi.org/10.1037/ccp0000495
   PubMed Web of Science ®Google Scholar
• Bagwell, G. A., Cesario, S. K., Fraser, D., Kenner, C., & Walker, K. (2023). Breaking the cycle of nursing chaos: The need to address the nursing shortage. Advances in Neonatal Care, 23(6), 495–498. https://doi.org/10.1097/ANC.0000000000001126
   PubMed Web of Science ®Google Scholar
• Buresh, M., Stern, R., & Rastegar, D. (2021). Treatment of opioid use disorder in primary care. BMJ: British Medical Journal, 373, n784. https://doi.org/10.1136/bmj.n784
   Web of Science ®Google Scholar
• Compton, W. M., & Volkow, N. D. (2021). Extended-release buprenorphine and its evaluation with patient-reported outcomes. JAMA Network Open, 4(5), e219708. https://doi.org/10.1001/jamanetworkopen.2021.9708
   PubMed Web of Science ®Google Scholar
• Coughlin, L. N., Salino, S., Jennings, C., Lacek, M., Townsend, W., Koffarnus, M. N., & Bonar, E. E. (2023). A systematic review of remotely delivered contingency management treatment for substance use. Journal of Substance Use and Addiction Treatment, 147, 208977. https://doi.org/10.1016/j.josat.2023.208977
   PubMedGoogle Scholar
• Dallery, J., Defulio, A., & Raiff, B. R. (2023). Digital contingency management in the treatment of substance use disorders. Policy Insights from the Behavioral and Brain Sciences, 10(1), 51–58. https://doi.org/10.1177/23727322221144648
   Google Scholar
• Davis, D. R., Kurti, A. N., Skelly, J. M., Redner, R., White, T. J., & Higgins, S. T. (2016). A review of the literature on contingency management in the treatment of substance use disorders, 2009–2014. Preventive Medicine, 92, 36–46. https://doi.org/10.1016/j.ypmed.2016.08.008
   PubMed Web of Science ®Google Scholar
• Farrell, M., Shahbazi, J., Byrne, M., Grebely, J., Lintzeris, N., Chambers, M., Larance, B., Ali, R., Nielsen, S., Dunlop, A., Dore, G. J., McDonough, M., Montebello, M., Nicholas, T., Weiss, R., Rodgers, C., Cook, J., Degenhardt, L., & CoLAB study team. (2022). Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. International Journal of Drug Policy, 100, 103492. https://doi.org/10.1016/j.drugpo.2021.103492
   PubMed Web of Science ®Google Scholar
• Holtyn, A. F., Toegel, F., Novak, M. D., Leoutsakos, J. M., Fingerhood, M., & Silverman, K. (2021). Remotely delivered incentives to promote buprenorphine treatment engagement in out-of-treatment adults with opioid use disorder. Drug and Alcohol Dependence, 225, 108786. https://doi.org/10.1016/j.drugalcdep.2021.108786
   PubMed Web of Science ®Google Scholar
• Khazanov, G. K., Morris, P. E., Beed, A., Jager-Hyman, S., Myhre, K., McKay, J. R., Feinn, R. S., Boland, E. M., & Thase, M. E. (2022, June). Do financial incentives increase mental health treatment engagement? A meta-analysis. Journal of Consulting and Clinical Psychology, 90(6), 528–544. PMID: 35771513. https://doi.org/10.1037/ccp0000737
   PubMed Web of Science ®Google Scholar
• Klostermann, K., & O’Farrell, T. J. (2013). Treating substance abuse: Partner and family approaches. Social Work in Public Health, 28(3–4), 234–247. https://doi.org/10.1080/19371918.2013.759014
   PubMed Web of Science ®Google Scholar
• Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137–145. https://doi.org/10.7326/M17-3107
   PubMed Web of Science ®Google Scholar
• Lee, J. D., Malone, M., McDonald, R., Cheng, A., Vasudevan, K., Tofighi, B., Garment, A., Porter, B., Goldfeld, K. S., Matteo, M., Mangat, J., Katyal, M., Giftos, J., & MacDonald, R. (2021). Comparison of treatment retention of adults with opioid addiction managed with extended-release buprenorphine vs daily sublingual buprenorphine-naloxone at time of release from jail. JAMA Network Open, 4(9), e2123032–e2123032. https://doi.org/10.1001/jamanetworkopen.2021.23032
   PubMed Web of Science ®Google Scholar
• Ling, W., Nadipelli, V. R., Solem, C. T., Ronquest, N. A., Yeh, Y. C., Learned, S. M., Mehra, V., & Heidbreder, C. (2020). Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study. Journal of Substance Abuse Treatment, 110, 1–8. https://doi.org/10.1016/j.jsat.2019.11.004
   PubMed Web of Science ®Google Scholar
• Luo, F., Li, M., & Florence, C. (2021). State-level economic costs of opioid use disorder and fatal opioid overdose—United States, 2017. Morbidity and Mortality Weekly Report, 70(15), 541. https://doi.org/10.15585/mmwr.mm7015a1
   PubMed Web of Science ®Google Scholar
• Lussier, J. P., Heil, S. H., Mongeon, J. A., Badger, G. J., & Higgins, S. T. (2006). A meta‐analysis of voucher‐based reinforcement therapy for substance use disorders. Addiction, 101(2), 192–203. https://doi.org/10.1111/j.1360-0443.2006.01311.x
   PubMed Web of Science ®Google Scholar
• Olmstead, T. A., & Petry, N. M. (2009). The cost-effectiveness of prize-based and voucher-based contingency management in a population of cocaine-or opioid-dependent outpatients. Drug and Alcohol Dependence, 102(1–3), 108–115. https://doi.org/10.1016/j.drugalcdep.2009.02.005
   PubMed Web of Science ®Google Scholar
• Petry, N. M. (2000). A comprehensive guide to the application of contingency management procedures in clinical settings. Drug & Alcohol Dependence, 58(1–2), 9–25. https://doi.org/10.1016/S0376-8716(99)00071-X
   PubMed Web of Science ®Google Scholar
• Petry, N. M. (2010). Contingency management treatments: Controversies and challenges [editorial]. Addiction, 105(9), 1507–1509. https://doi.org/10.1111/j.1360-0443.2009.02879.x
   PubMed Web of Science ®Google Scholar
• Petry, N. M. (2013). Contingency management for substance abuse treatment: A guide to implementing this evidence-based practice. Routledge.
   Google Scholar
• Petry, N. M., Alessi, S. M., Marx, J., Austin, M., & Tardif, M. (2005). Vouchers versus prizes: Contingency management treatment of substance abusers in community settings. Journal of Consulting and Clinical Psychology, 73(6), 1005. https://doi.org/10.1037/0022-006X.73.6.1005
   PubMed Web of Science ®Google Scholar
• Powers, M. B., Vedel, E., & Emmelkamp, P. M. (2008). Behavioral Couples Therapy (BCT) for alcohol and drug use disorders: A meta-analysis. Clinical Psychology Review, 28(6), 952–962. https://doi.org/10.1016/j.cpr.2008.02.002
   PubMed Web of Science ®Google Scholar
• Wainwright, J. J., Mikre, M., Whitley, P., Dawson, E., Huskey, A., Lukowiak, A., & Giroir, B. P. (2020). Analysis of drug test results before and after the US declaration of a national emergency concerning the COVID-19 outbreak. JAMA, 324(16), 1674. https://doi.org/10.1001/jama.2020.17694
   PubMed Web of Science ®Google Scholar
• Wang, L., Weiss, J., Ryan, E. B., Waldman, J., Rubin, S., & Griffin, J. L. (2021). Telemedicine increases access to buprenorphine initiation during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 124, 108272. https://doi.org/10.1016/j.jsat.2020.108272
   PubMed Web of Science ®Google Scholar